Tuesday, 17 November 2026 Every SEC filing alert, by company
ALFA USA Filings Every alert, straight from SEC EDGAR
News

NextCure, Inc.

NASDAQ: NXTC · Life Sciences · 7 alerts · CIK 1661059

Share price
$6.68Close, Nov 16
Market cap
$30.6M
Shares outstanding
4.58MLatest SEC cover page
Sector
Life Sciences
Industry
Pharmaceutical PreparationsSIC 2834

Today's reference numbers: shares from the company's latest SEC cover page, price from the latest market close. Not a valuation or a recommendation. All NextCure, Inc. filings on SEC EDGAR ↗

4:01 PM ET Form 4
Insider Buying

NextCure Insider ADAR1 Capital Management LLC Buys $62.9K of Stock

ADAR1 Capital Management LLC bought 12,333 shares of NextCure, Inc. at $5.10 a share, worth $62.9K in total on Nov 11, 2026. Shares held after the trade: 750,289 (+1.7%).

Value
$62.9K
Shares
12,333
Price
$5.10
Holding change
+1.7%
Trade date
Nov 11, 2026
4:16 PM ET 8-K
M&A Deal

NextCure Signs $820M M&A Deal with Avere Therapeutics, Inc.

NextCure provided a status update on its pending merger with Avere Therapeutics, noting that the SEC has declared its S-4 registration statement effective and a stockholder vote is scheduled for December 9, 2026. The transaction is supported by $820 million in committed financing from a syndicate of healthcare investors to fund the development of Avere's lead inflammatory disease program, AVR-001.

Value
$820M
Counterparty
Avere Therapeutics, Inc.

“During the third quarter, we continued to execute on the strategic initiatives associated with our proposed merger with Avere Therapeutics. Importantly, total financing commitments supporting the proposed transaction increased to approximately $820 million from a syndicate of leading healthcare-focused and institutional investors. We believe this significant financing commitment reflects strong confidence in Avere's clinical development strategy and the potential of AVR-001, while enhancing the opportunity to create long-term value for NextCure stockholders.”

Michael Richman, President and CEO of NextCure
4:20 PM ET Form 4
Insider Buying

NextCure Insider ADAR1 Capital Management LLC Buys $18.7K of Stock

ADAR1 Capital Management LLC bought 3,662 shares of NextCure, Inc. at $5.10 a share, worth $18.7K in total on Nov 6, 2026. Shares held after the trade: 737,956 (+0.5%).

Value
$18.7K
Shares
3,662
Price
$5.10
Holding change
+0.5%
Trade date
Nov 6, 2026
8:00 AM ET 8-K
Leadership Change

NextCure Leadership Change

NextCure, Inc. announced that Chief Medical Officer Dr. Udayan Guha will be terminated effective October 31, 2026. The departure is in contemplation of the company's pending merger with Avere Therapeutics, Inc. Dr. Guha will receive severance benefits consistent with a termination without cause, including enhanced benefits if the merger closes.

7:36 PM ET Form 4
Insider Buying

NextCure Insider ADAR1 Capital Management LLC Buys $45.3K of Stock

ADAR1 Capital Management LLC bought 9,179 shares of NextCure, Inc. at $4.83 to $5.10 a share (average $4.93) in 2 transactions, worth $45.3K in total between Oct 23, 2026 and Oct 27, 2026. Shares held after the trade: 733,270 (+0.5%).

Value
$45.3K
Shares
9,179
Average price
$4.93
Holding change
+0.5%
Trade date
Oct 23, 2026 to Oct 27, 2026

Get Alerts

Get ALFA Finder alerts first

Real-time SEC filing alerts for US stocks are launching soon. Leave your details and we'll tell you the moment they go live.